Buqaileh Raghad, Alshriem Lubna A, AbouAlaiwi Wissam
Department of Pharmacology and Experimental Therapeutics, University of Toledo, Toledo, OH 43614, USA.
Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, P.O. Box 3030, Irbid 22110, Jordan.
Int J Mol Sci. 2025 May 22;26(11):4971. doi: 10.3390/ijms26114971.
Polycystic kidney disease (PKD), a ciliopathy caused primarily by mutations in the and genes, disrupts renal structure and function, leading to progressive renal failure. The primary cilium, a sensory organelle essential for cellular signaling, plays a pivotal role in maintaining renal function. Among its signaling components, G-protein-coupled receptors (GPCRs) within the cilium have gained significant attention for their localized functions and their contribution to PKD pathogenesis. Dysfunction of ciliary GPCR signaling alters key downstream pathways, including mammalian target of rapamycin (mTOR), cyclic adenosine monophosphate (cAMP), and calcium homeostasis, exacerbating cyst formation and disease progression. Additionally, interactions between ciliary GPCRs and PKD-associated proteins, such as Polycystin-1 (PC1) and Polycystin-2 (PC2), underline the complexity of PKD mechanisms. Recent advances highlight GPCRs as promising therapeutic targets for ciliopathies, including PKD. Emerging GPCR modulators and drugs in clinical trials show the potential to restore ciliary signaling and attenuate disease progression. This paper explores the physiological functions of ciliary GPCRs, their mechanistic links to PKD, and the therapeutic implications of targeting these receptors, offering insights into future research directions and therapeutic strategies for PKD.
多囊肾病(PKD)是一种主要由 和 基因的突变引起的纤毛病,会破坏肾脏结构和功能,导致进行性肾衰竭。初级纤毛是细胞信号传导所必需的感觉细胞器,在维持肾功能方面起着关键作用。在其信号传导成分中,纤毛内的G蛋白偶联受体(GPCR)因其局部功能及其对PKD发病机制的贡献而受到了广泛关注。纤毛GPCR信号传导功能障碍会改变关键的下游途径,包括雷帕霉素哺乳动物靶点(mTOR)、环磷酸腺苷(cAMP)和钙稳态,加剧囊肿形成和疾病进展。此外,纤毛GPCR与PKD相关蛋白(如多囊蛋白-1(PC1)和多囊蛋白-2(PC2))之间的相互作用,突显了PKD机制的复杂性。最近的进展突出了GPCR作为包括PKD在内的纤毛病的有前景的治疗靶点。临床试验中出现的GPCR调节剂和药物显示出恢复纤毛信号传导和减轻疾病进展的潜力。本文探讨了纤毛GPCR的生理功能、它们与PKD的机制联系以及靶向这些受体的治疗意义,为PKD的未来研究方向和治疗策略提供了见解。